Engineering Novel Nanoparticles to Enhance Chemotherapy for Local Recurrence and Distant Metastasis

Addressing local recurrence and distant metastasis is a challenging barrier to overcome in the successful treatment of solid tumors. To meet this end, chemotherapeutic drug-loaded nanoparticles have been rationally synthesized to improve the efficacy of the anti-cancer drugs. To facilitate the evaluation, we developed several clinical-relevant models including local recurrence models following surgical resection and metastatic breast cancer models. We found that the nanoparticles had higher affinity to tumor tissues than normal tissues. The delivery systems yield over 100 times higher drug levels in tumor tissues. The survival times were more than 2.5 times longer compared to traditional treatments. The nanoparticles have been further improved based on the feedbacks from the in vivo evaluations.

Dr. Rong Liu earned his M.D. degree from Xuzhou Medical College and his Ph.D. from Tongji Medical College, Huazhong University of Science and Technology, China. After he finished his post-doctoral training in acute lung injury at the Massachusetts General Hospital (MGH), he joined the Lab of Dr. Yolonda Colson at Brigham and Women’s Hospital, collaborating with the Lab of Professor Mark Grinstaff at Boston University to study local anti-cancer therapies by means of polymeric drug-delivery systems. Currently at MGH, he evaluates several nanoparticle and polymeric film formulations to treat local recurrence of lung cancer and sarcoma, metastatic breast cancer, and carcinomatosis in in vivo models. He is also an Instructor in Surgery at the Harvard Medical School.